Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Tonu Vanakesa, Oleg Gladkov, Katalin Udud, Patrick Therasse, Byoung Chul Cho, Jean-Louis Pujol, Moon Soo Kim, Libor Havel, Johan Vansteenkiste, Hans Hoffman, Nasser K. Altorki, Haruhiko Kondo, Paul D. Taylor, Jacek Jassem, Marcin Zieliński, Mei Lin Liao, Jamila Louahed, Tetsuya Mitsudomi, Tommaso De Pas, Konstantinos Zarogoulidis, Anders Bugge, Jubrail Dahabreh, Vincent Brichard, Muriel Debois, Haruhiku Nakayama, Jianxing He, Hirohito Tada, Masahiro Yoshimura, Emilio Esteban Gonzalez, C. Debruyne

Publikováno v: The Lancet Oncology. 17:822-835

Summary Background Fewer than half of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no substantial progress has been made in adjuvant treatment. We aimed t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cfba095f4c0d44aa7a2da0e05af827f
https://doi.org/10.1016/s1470-2045(16)00099-1

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Autor: Suman Redhu, Katalin Udud, Myung-Ju Ahn, Sang We Kim, George R Blumenschein, Dong Wan Kim, T. De Pas, David Planchard, Frank S. Wu, A. Puski, Nasser H. Hanna, E. Rappold, Julien Mazieres, Paul Baas, Jacques Cadranel, Pasi A. Jänne, Egbert F. Smit, Frank Dunphy, Joo Hang Kim

Publikováno v: Blumenschein, G R, Smit, E F, Planchard, D, Kim, D W, Cadranel, J, De Pas, T, Dunphy, F, Udud, K, Ahn, M J, Hanna, N H, Kim, J H, Mazieres, J, Kim, S W, Baas, P, Rappold, E, Redhu, S, Puski, A, Wu, F S & Janne, P A 2015, ' A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) ', Annals of Oncology, vol. 26, no. 5, pp. 894-901 . https://doi.org/10.1093/annonc/mdv072
Annals of Oncology, 26(5), 894-901. Oxford University Press

KRAS mutations in non-small-cell lung cancer (NSCLC) are associated with poor prognosis. Trametinib, a selective inhibitor of MEK1/MEK2, demonstrated similar efficacy to docetaxel in patients with advanced KRAS-mutant NSCLC, with median progression-f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a960ade09f0d01ca09822cb7f2ae860
https://research.vumc.nl/en/publications/9866d163-146f-4690-96b1-510657283a42

Lung cancer in smoking patients inversely alters the activity of hOGG1 and hNTH1

Autor: Sataro Goto, Ildiko Horvath, Zsolt Papai, Zsolt Radak, Katalin Udud, Hideko Nakamoto

Publikováno v: Cancer letters. 219(2)

N-Glycosylases excise the damaged adducts from DNA. 7,8-Dihydro-8-oxoguanine in human cells is repaired by OGG1 and hNTH1. The activities of hOGG1 and hNTH1 were measured, using modified and 32P labelled oligonucleotides, in bronchial biopsy samples

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b5068eab8db1acd58092d34f5a77f2
https://pubmed.ncbi.nlm.nih.gov/15723719

MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non–small cell lung cancer (NSCLC)

Autor: Myung-Ju Ahn, David Planchard, Frank S. Wu, Sang-We Kim, Katalin Udud, Julien Mazieres, Egbert F. Smit, Tommaso De Pas, Joo Hang Kim, Paul Baas, Frank Dunphy, Michael R. W. Streit, Jacques Cadranel, George R. Blumenschein, Kevin M. Bellew, Suman Redhu, E. Rappold, Dong Wan Kim, Pasi A. Jänne, Nasser H. Hanna

Publikováno v: Journal of Clinical Oncology. 31:8029-8029

8029 Background: KRAS mutations are detected in 25% of NSCLC, and there are no approved targeted therapies for this subset of NSCLC. D, an approved second-line treatment for NSCLC, has a response rate of < 10%. T is a reversible, highly selective all

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60774c089f410a59a07d20e73b7cd111
https://doi.org/10.1200/jco.2013.31.15_suppl.8029